



AJINOMOTO®

AJINOMOTO PHARMACEUTICALS LAUNCHES MOVIPREP®, A NEW ORAL BOWEL CLEANSING AGENT IN JAPAN

London 4 June 2013. Norgine today announced that its partner Ajinomoto Pharmaceuticals is launching MOVIPREP in Japan for bowel preparation prior to colonoscopy and colon surgery. MOVIPREP was included onto Japan's National Health Insurance drug price standard list on 31 May 2013.

Ajinomoto acquired the Japanese rights for MOVIPREP from Norgine in 2008. Ajinomoto has developed a new flavour of MOVIPREP to meet the tastes and preferences of Japanese patients together with a new and innovative user-friendly packaging that led to its marketing authorisation. In addition to its proven efficacy and safety, MOVIPREP also offers benefits to patients in terms of a reduced dosage volume.

MOVIPREP was originally developed by Norgine and is available in Europe and North America and is the world's most frequently administered branded bowel preparation prior to colonoscopy and other procedures requiring a clean bowel.

Paul Pay, Norgine Vice President Corporate & Business Development said; "The availability of MOVIPREP in Japan provides patients with a world-leading effective treatment that is proven to provide a clear view of the colon, which is paramount to help detect bowel diseases such as colorectal cancer and prepare the colon prior to surgery. We are pleased to be able to launch MOVIPREP in Japan through such a strong partnership and look forward to continuing our excellent relationship with Ajinomoto."

ENDS

About Norgine

Norgine is a successful, independent European specialty pharmaceutical company that has been established for over 100 years and has a presence in all major European markets. In 2012, Norgine's net product sales were c€250 million and the company employs over a 1,000 people.

Norgine's focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, critical and supportive care.

The Company currently markets a range of products in various markets in its key therapeutic areas: MOVICOL® for the treatment of constipation and faecal impaction, MOVIPREP® a bowel preparation for use prior to any procedure that requires a clean colon, KLEAN-PREP®
[PR2013May29.02](#)

**Norgine - Norgine House - Widewater Place
Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600**

for large bowel preparation prior to colonoscopy or surgery, XIFAXAN® /XIFAXANTA™) for the treatment of travellers' diarrhoea, XIFAXAN 550/TARGAXAN® 550 for the reduction in recurrence of episodes of overt hepatic encephalopathy, ORAMORPH® for the treatment of moderate to severe pain associated with cancer and our supportive care portfolio: SAVENE®, DANTRIUM®, XEROTIN® and PROTHER®.

Norgine is active in research and development and currently has products in various stages of clinical development. Norgine manufactures most of its own products in Hengoed, UK and Dreux, France. For more information: www.norgine.com.

Media Contacts

Isabelle Jouin: + 44 (0) 771 406 1327

Julie Hornby Winfield : +44 (0)1895 826600

About Ajinomoto and Ajinomoto Pharmaceuticals

Ajinomoto is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Ajinomoto Pharmaceuticals, responsible for pharmaceutical business in Ajinomoto group, provides unique products, specializing in gastrointestinal diseases and metabolic diseases.

For more information: <http://www.ajinomoto-seiyaku.co.jp/en/index.html>

Media contact

Ajinomoto Pharmaceuticals Co., Ltd.

Corporate Planning Dept. TEL: +81-(0)3-6280-9802

FAX: +81-(0)3-6280-9912

* MOVIPREP and モビプレップ are registered trademarks of Norgine Group.

MOVIPREP® was originally developed by Norgine B.V. (the Netherlands). Ajinomoto Pharmaceuticals have licensed the exclusive rights to develop, manufacture and sell MOVIPREP® in Japan market.

PR2013May29.02

Norgine - Norgine House - Widewater Place

Moorhall Road - Harefield - Uxbridge - UB9 6NS - UK - Tel: +44 (0) 1895 826 600